A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Surgically Menopausal Women.

Trial Profile

A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Surgically Menopausal Women.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2012

At a glance

  • Drugs Testosterone (Primary)
  • Indications Decreased libido
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Feb 2012 Actual patient number (626) added as reported by ClinicalTrials.gov.
    • 06 Feb 2012 Actual end date January 2012 added as reported by ClinicalTrials.gov.
    • 06 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top